TPO may be able to signal in the presence of ruxolitinib through JAK‐independent pathways in the same way that erythropoietin increased erythropoiesis in CLL patients on ruxolitinib as a single agent.10 Alternatively, blood levels of IL10 decreased in all patients on ruxolitinib (Figure 4A). The gene discussed is TPO; the disease is B-cell chronic lymphocytic leukemia.